Comparing two different skin treatments to restore Color in Vitiligo patches: A study using patients own skin cells and a new printing technology

Comparison of Non-Cultured Epidermal Cell Suspension (NCES) and 3D Bioprinting of Autologous Melanocytes for the Treatment of Vitiligo: A Pilot Study - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/11/077162

Enrollment

Registered

2024-11-21

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: 3D bioprinting: For 3D bioprinting, autologous skin samples will be taken from the patients with vitiligo using dermatome after local anestheseia with injection lignocaine (donor area),

Eligibility

Inclusion criteria

Inclusion criteria: (a) Stable vitiligo for at least 12 months. (b) Age between 18-45 years. (c) Vitiligo patches located on accessible body areas (face, limbs, torso). (d) No prior cellular transplantation on the selected patches.

Exclusion criteria

Exclusion criteria: (a) Active vitiligo. (b) Comorbid conditions such as diabetes or autoimmune diseases. (c) Pregnancy or lactation. (d) History of keloid or hypertrophic scar formation.

Design outcomes

Primary

Measure	Time frame
Rate of repigmentation of vitiligo patchesTimepoint: over 3 to 4 months	—

Secondary

Measure	Time frame
(a) Patient Satisfaction (b) Safety & Tolerability (c) Feasibility of 3D Bioprinting ProcessTimepoint: 6 to 7 months	—

Countries

India

Contacts

Public ContactDr Debdeep Mitra

Command Hospital Air Force Bangalore, Indian Air Force

debdeep5000@gmail.com08811851830

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 15, 2026